Participants will be given the assigned injection once each week for about 40 weeks. During the study they will attend regular clinic visits where a simple blood test called Hemoglobin A1c (HbA1c) will be used to measure average blood sugar over the past few months, along with routine safety checks. The study is designed so that neither the participants nor the study staff know which injection is being given, helping to keep the results unbiased.

This clinical trial is focused on studying Type 1 Diabetes in adults who are also overweight or have obesity. The treatment being tested is called tirzepatide (also known by its code name LY3298176), which is given as a solution for injection using a pre-filled pen. The purpose of the study is to see if tirzepatide can help control blood sugar levels better than a placebo.

Participants in the study will receive either tirzepatide or a placebo once a week. The study will last for about 40 weeks. During this time, the effects of tirzepatide on blood sugar levels will be closely monitored. The study aims to determine if tirzepatide is more effective than a placebo in managing blood sugar levels in people with Type 1 Diabetes.

This study is important for understanding how tirzepatide can help people with Type 1 Diabetes who are also dealing with being overweight or obese. The results could provide valuable insights into new treatment options for better managing blood sugar levels in these individuals.

The main goal of the research is to find out which individuals respond best to the treatment. Participants will receive the medication for about six months, with visits at the beginning and end of the period to collect information on weight, eating behavior, and other health measures.

Key outcomes include changes in BMI (a number that compares weight to height), changes in the Binge Eating Scale (a questionnaire that measures the severity of binge eating), as well as waist‑to‑hip ratio, body composition, appetite feelings, and various blood markers. Simple explanations are provided for any technical terms, such as BMI being a standard way doctors assess whether weight is in a healthy range.

The purpose of the trial is to confirm that EMP22 produces the same effect as the already approved drug Xenical® in terms of how much fat is expelled in the stool, a measure known as faecal fat excretion. This type of comparison is called pharmacodynamics, which looks at what the drug does to the body.

Healthy volunteers will take the study capsules in two separate parts. In the first part, participants will receive EMP22 and Xenical® in a single‑blind crossover design, meaning they will not know which capsule they are taking each time, but the study staff will. In the second part, the focus shifts to how the body processes the medicines, referred to as pharmacokinetics, by giving EMP16 and comparing it to Xenical®. Participants will follow a short schedule of taking the capsules, providing stool samples, and having a few blood draws to assess how the medicines work and are handled by the body.

The study follows a short treatment period after semaglutide is given. During this time, the study team checks how well the medicine is tolerated and records common stomach and body symptoms such as nausea, vomiting, constipation, diarrhoea, abdominal pain, dizziness, fatigue, headache, appetite changes, and changes in body weight. The main focus is on how strong nausea is during the first few days after treatment.

The trial is randomised, which means the study treatment is assigned by chance, and double-blind, which means neither the participants nor the study team know who receives which treatment during the study. The trial is also placebo-controlled, so one group receives placebo instead of the active added medicine.

Both medicines are given as a subcutaneous injection, which means an injection under the skin, once a week. People in the study receive one of several dose plans of NNC0487-0111 or semaglutide, and some study groups receive placebo. The study follows changes in body weight, blood sugar, waist size, blood pressure, and other health measures over time. It also looks at side effects, including low blood sugar, which can happen when blood sugar drops too far.

The study is planned to run for a long period, with treatment and follow-up visits spread across the study time. The medicines are given in a pre-filled pen, and the course of the study is designed to compare how the different treatments work and how safe they are in adults with excess body weight and type 2 diabetes.

The study lasts about 72 weeks. People in the study are placed into different groups by chance, and neither the participants nor the study team know who receives RO7795068 or placebo during the study. Before treatment starts, a first check is done. After that, the medicine is given regularly, and follow-up visits continue through the study period to monitor weight, blood sugar, and overall health.

The study also looks at changes related to HbA1c, a blood test that shows average blood sugar over time, as well as waist size, blood pressure, cholesterol, and possible side effects. It also checks how the treatment may affect daily physical function and quality of life.

The purpose of the study is to see if MET097 helps participants lose more weight than the placebo after about 64 weeks. Throughout the trial, participants will visit the clinic regularly for weight checks, safety assessments, and blood tests, including a measurement of HbA1c, a test that shows the average blood‑sugar level over the past two to three months. Additional evaluations will monitor changes in cholesterol, blood pressure, and overall health status, and the study will continue with follow‑up visits for up to roughly 84 weeks.

The focus of the research is to observe changes in body weight, Body Mass Index (a measure of body fat based on height and weight), and body fat composition. The study also monitors for any potential complications related to the original liver disease or the treatment itself. Additionally, the research tracks how patients fare after their transplant, looking at survival rates and the health of the new organ during the months following the surgery.

People in the study are assigned by chance to receive either RO7795068 or placebo, and neither the participants nor the study team know which one is being given. The study lasts for about 72 weeks. During this time, the treatment is given regularly, and the study team checks body weight, general health, and possible side effects. The study also looks at changes in waist size, blood sugar, blood fats, blood pressure, eating habits, and quality of life.

Possible side effects, changes in blood tests, heart tracing results, and other safety checks are monitored throughout the study. The trial is designed to find out whether RO7795068 can help with weight management in adults with obesity or overweight who do not have type 2 diabetes.

The purpose of the study is to see how well KAI-9531 works and how safe it is. Participants are assigned by chance to receive either KAI-9531 or placebo, and neither the participants nor the study team know which treatment is being given during the study. The study continues for a long period while regular injections are given and health is followed over time.

During the study, body weight and other health measures are checked at planned visits. The study looks at changes in weight, waist size, blood pressure, blood fats such as triglycerides and cholesterol, blood sugar, and quality of life related to physical function. Safety is also monitored through medical checks, blood tests, heart tracing with ECG, and review of any side effects.

People in the study are assigned by chance to receive either KAI-9531 or placebo, and neither the participants nor the study team know which one is being given during the trial. Treatment is given over a long period, with regular study visits while the injections continue. The purpose of the study is to understand the efficacy and safety of KAI-9531 in people living with obesity or overweight and diabetes.

During the study, body weight, blood sugar, and other health measures are checked over time. The study also looks at possible side effects and at whether the body makes antibodies, which are proteins the immune system can form against a medicine. This information helps show how the treatment works and how safe it is for people taking it.

The purpose of the study is to see how well NNC0487-0111 helps people with obesity lose weight and to check its safety. People in the trial will receive weekly treatment over a period of time, and the study will follow changes in body weight and other health measures during the trial. The study may also look at body size, blood pressure, blood sugar, blood fats, and signs of inflammation, as well as any side effects.

The trial is designed to compare different amounts of the study medicine with placebo, and some people may continue into an extension phase, which means treatment and follow-up may last longer. The overall study is planned to run for several years.

People in the study receive one of several weekly dose levels of NNC0487-0111 or placebo. The treatment is given with a pre-filled pen and the study lasts for many months. During the study, body weight, blood sugar control, and other health changes are followed, along with any unwanted effects.

The study is designed to find out whether NNC0487-0111 can help reduce body weight in people who have excess body weight and type 2 diabetes. It also looks at changes in waist size, blood sugar, blood pressure, blood fats, and quality of life, as well as safety issues such as low blood sugar and other side effects.

Participants in this trial will receive subcutaneous injection, which is a method of delivering medication into the fatty layer of the skin just below the surface. The treatment KAI-9531 or semaglutide will be administered once every week. The study is designed to observe changes in body weight and other health factors over a period of time.

Participants in the study will receive either maridebart cafraglutide or a placebo over a period of 72 weeks. Throughout the study, changes in body weight, waist circumference, and other health markers such as blood pressure and blood sugar levels will be monitored. The study will also assess the impact of weight changes on the quality of life of the participants.

The study aims to provide valuable information on the effectiveness and safety of maridebart cafraglutide for managing weight in individuals with Type 2 Diabetes Mellitus. This research could potentially lead to new treatment options for those struggling with weight management in the context of diabetes.

Participants in the study may receive cagrilintide alone, the combination of cagrilintide and semaglutide, semaglutide alone, or a placebo. The study involves monitoring changes in Body Mass Index, which is a measurement used to determine if a person has a healthy weight for their height, and the BMI Standard Deviation Score, a calculation that compares a person’s body mass to the average for others of the same age and sex. The course of the study involves weekly injections over a period of time to observe how these substances affect body weight and overall health.

The research involves monitoring several health factors during the study period. These factors include changes in Body Mass Index, which is a way to measure body fat based on height and weight, and waist circumference. Additionally, measurements will be taken regarding systolic blood pressure and diastolic blood pressure, which represent the pressure in the arteries when the heart beats and when it rests. Other monitored aspects include blood sugar levels, such as glycated haemoglobin, and various types of lipids, which are fats found in the blood like cholesterol and triglycerides.

The purpose of this study is to find out if CagriSema can improve markers that show how chronic kidney disease is progressing in people with type 2 diabetes who are living with overweight or obesity. Participants may also be taking other medicines during the study, such as enalapril maleate, dapagliflozin propanediol, or finerenone, which are used to help protect the kidneys and manage related conditions. The study will measure changes in urine protein levels, kidney function, body weight, waist size, blood sugar control, and blood pressure. It will also track any side effects or health problems that occur during treatment.

During the study, participants will receive their assigned treatment for up to 35 weeks. They will attend regular visits where measurements will be taken and blood and urine samples will be collected to check how well the treatment is working and to monitor safety. The study team will look at changes from the start of the study to the end of treatment to understand the effects of each treatment option.

During the study, patients will be prepared for surgery that requires a breathing tube. They will receive oxygen before the procedure begins. Then they will be given medications to put them to sleep and relax their muscles. The muscle relaxing medication will be given in a dose that is calculated either based on what the patient should ideally weigh or based on what they actually weigh. The doctor will then place the breathing tube and evaluate how easy or difficult it was to do this. The time it takes to place the tube will be measured, and the level of muscle relaxation will be checked. The oxygen levels in the blood will be monitored throughout the procedure.

The study will look at whether excellent conditions for placing the breathing tube are achieved with either dosing method. It will also examine how many patients have acceptable conditions for tube placement, how long it takes to successfully place the tube, and whether any extra techniques are needed to get a better view of the airway. The study will record oxygen levels at different times during the procedure and track any problems that occur, such as drops in oxygen levels or changes in blood pressure. The study is expected to begin enrolling patients in October 2025 and continue until the end of 2028.

During the study, participants will receive either cagrilintide at different dose levels or placebo for a treatment period of up to 64 weeks. All participants will also receive guidance on lifestyle changes to support weight management. The study will measure changes in body weight and track how many people achieve weight loss of at least 5%, 10%, or 15% of their starting weight. Other measurements will include changes in waist size, blood sugar control measured by HbA1c (a test that shows average blood sugar levels over time), blood pressure, and various blood fats such as cholesterol and triglycerides.

The study will also assess quality of life using questionnaires that ask about physical function and overall well-being, and will monitor any side effects or health problems that occur during treatment. Safety will be carefully tracked, including any episodes of low blood sugar, which can happen when blood sugar drops below normal levels. Participants may continue taking their usual diabetes medications during the study if they have been on a stable dose for a certain period before joining.

The purpose of the study is to evaluate how different forms and doses of semaglutide affect the way blood clots in these specific groups. One group of participants will use Rybelsus, which is an oral tablet, while another group may use Wegovy, which is a subcutaneous injection, meaning it is administered through a needle just under the skin. Some participants will receive a placebo or compare these treatments against existing medications like acetylsalicylic acid.

During the study, participants will follow a specific treatment plan involving either tablets or injections over a set period. Researchers will monitor various biological markers, including indicators of inflammation and how well the blood vessels are functioning, to observe changes in the body’s response to the medications.

During the study, participants will receive either Eloralintide or a placebo through subcutaneous use, which means the medication is injected into the fatty tissue just under the skin. The medication is provided in a pre-filled syringe for once-weekly administration. This is a randomized and double-blind study, meaning that neither the participants nor the researchers know beforehand which treatment is being administered. This method is used to ensure the results are as objective as possible.

The aim is to find out whether adding the new medication to standard treatment lowers the chance of dying from heart‑related causes, being hospitalized for heart failure, or needing urgent care for heart failure.

Participants will receive a dose once a week for several months and will attend regular visits where simple checks such as blood pressure, weight, and short questionnaires are done. The study follows each person over time to see how often the listed heart events occur and to monitor safety through routine lab tests.

Participants in the study will receive either the test medication or a placebo. The medication is administered through a subcutaneous injection, which means it is delivered into the fatty layer of tissue just under the skin, using a pre-filled pen once per week. During the study, changes in body weight, waist size, and various health measurements will be monitored. Additionally, the impact on knee pain, stiffness, and physical movement will be observed to see how the treatment affects daily function.

Participants will receive the treatment through a subcutaneous injection, which means the medicine is administered into the fatty layer of tissue just under the skin, using a pre-filled pen once a week. Throughout the study, changes in body weight and levels of pain in the knee will be observed. Other factors such as physical function, waist size, and certain blood measurements like cholesterol and blood pressure may also be monitored to understand the overall impact of the treatment.

Participants in this study will be assigned to receive either MET097 or a placebo. The study is designed to compare how much body weight changes over a specific period of time. During the course of the trial, individuals will receive their assigned treatment once every week. The process involves monitoring weight changes and other health factors over a long period, extending up to 84 weeks, to observe the impact of the medication on overall health.

Participants in the study will receive either the study drug or a placebo through a subcutaneous injection, which means the medicine is delivered by a needle into the fatty layer of tissue just under the skin. The medication is provided as a solution for injection in a pre-filled syringe and is intended to be used once every week. This research is designed to determine if Eloralintide can lead to a greater reduction in body weight compared to the placebo over a period of time.

Participants in the study will receive weekly injections of either Tirzepatide or a placebo over a period of 17 weeks. Throughout the study, researchers will monitor changes in the participants’ body mass index (BMI), which is a measure of body fat based on height and weight. The study aims to see if Tirzepatide can help reduce BMI and improve other health conditions related to being overweight or having obesity.

The trial is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving Tirzepatide and who is receiving the placebo. This helps ensure that the results are unbiased. The study is expected to continue until early 2026, with the recruitment of participants starting in late 2023. The findings from this trial could provide valuable insights into the potential benefits of Tirzepatide for adolescents struggling with weight management and related health issues.

Participants will receive one injection of the vaccine into a muscle. Blood samples will be taken before the vaccination and again 14 days after the vaccination to measure the level of antibodies, which are proteins that help fight off infections. The study will check how many people reach a protective level of antibodies and how many people have a significant increase in antibody levels after vaccination. The vaccine contains inactive flu virus particles that cannot cause the flu but help the body build protection against it.

During the study, any side effects will be recorded, including reactions at the injection site such as pain or redness, and general symptoms like fever or tiredness that may occur in the week after vaccination. Any serious health problems or unexpected reactions will also be monitored throughout the entire study period. The study will compare the vaccine response between different groups including people with obesity, people with obesity and diabetes, people with normal weight, and pregnant women with and without obesity.

The purpose of this study is to compare different doses of AMG 133 to placebo to see how well they work in helping people lose weight and keep it off over a period of time. The study will look at two groups of people: those who have weight problems without diabetes and those who have weight problems with type 2 diabetes. The study will measure how much weight people lose and whether they can maintain that weight loss.

During the study, participants will receive treatment for up to 104 weeks, which is about two years. The study will track changes in body weight, blood sugar levels measured by a test called hemoglobin A1c or HbA1c, waist size, blood pressure, and various substances in the blood such as cholesterol and triglycerides. Some participants will also have body composition measured using a scanning method called dual-energy X-ray absorptiometry or DXA, which shows how much fat and muscle the body has. The study will also monitor how the medication moves through the body and check for any side effects to determine if the treatment is safe and well-tolerated.

Tirzepatide is given as an injection under the skin using a pre-filled pen once a week. The study will compare people taking tirzepatide to people taking placebo to see if there is a difference in major health events. These events include death from any cause, heart attack that is not fatal, stroke that is not fatal, procedures to restore blood flow to the heart, or problems related to heart failure. The study is looking at whether tirzepatide can help prevent these serious health problems in people who are overweight or have obesity and also have heart disease or risk factors for heart disease such as smoking, abnormal levels of fats in the blood, high blood pressure, or kidney disease.

People in the study will continue taking the treatment for a period of time while doctors monitor their health and track whether any of these major health events occur. The study will measure how long it takes until the first occurrence of any of these serious health problems happens in people taking tirzepatide compared to those taking placebo. The treatment period can last up to 324 weeks.

The purpose of the study is to see how well the combination medicine helps people with excess body weight lose weight compared to placebo, when used together with eating fewer calories and doing more physical activity. The study will look at how much body weight people lose and how many people achieve certain weight loss goals.

People taking part in the study will receive weekly injections under the skin for a treatment period that can last up to several weeks. During the study, different measurements will be taken to see how the treatment is working, including body weight, waist size, blood pressure, and various blood fat levels such as cholesterol and triglycerides. The study will compare the results between people who receive the active medicine and those who receive placebo.

The purpose of this study is to find out how well CagriSema works in helping people lose weight compared to placebo, when used together with diet and exercise changes. The study will also look at whether people can achieve certain weight loss goals, such as losing at least five percent or twenty percent of their body weight. Additionally, the study will examine how the treatment affects waist size, blood sugar control measured by a test called HbA1c, blood pressure, and quality of life related to physical function. The safety of the treatment will be carefully monitored by tracking any unwanted effects that occur during the study, including episodes of low blood sugar.

During the study, participants will receive their assigned treatment for up to one year. Throughout this time, they will have regular visits where doctors will check their weight, blood sugar levels, blood pressure, and overall health. The study will collect information about how the treatment affects the body and whether it causes any side effects. This research aims to provide information about whether this combination treatment could be a helpful option for people with type 2 diabetes who are also struggling with excess weight.

The purpose of this research is to determine if cagrilintide is more effective than placebo in helping people lose weight. The study will specifically look at whether the medication can help people achieve a reduction of at least 5% of their body weight. During the study, participants will receive either cagrilintide or placebo injections for approximately 64 weeks.

The study will measure various health indicators including changes in body weight, waist size, blood pressure, and different types of cholesterol in the blood. It will also assess how the treatment affects quality of life and overall health. Throughout the study, participants’ safety will be monitored by tracking any side effects that may occur.

During the study, participants will be given either a type of general anesthesia that contains no opioid medications or the standard anesthesia that includes opioids. After surgery, researchers will monitor how much nausea and vomiting patients experience, along with their pain levels and need for additional pain medication during the first 24 hours following surgery.

The purpose of this research is to evaluate how well orforglipron tablets taken once daily work compared to placebo in reducing body weight in people without diabetes and improving blood sugar control in those with diabetes. The study consists of two parts: one for participants with obesity or overweight who have at least one weight-related health condition but do not have diabetes, and another for those who have both weight issues and Type 2 Diabetes.

Participants will first go through a screening period of about 4 weeks before being enrolled in the appropriate study group based on whether they have diabetes. The treatment period will last 40 weeks, during which participants will take either orforglipron or placebo. For diabetes patients, hemoglobin A1c (a measure of average blood sugar levels over 2-3 months) will be monitored to assess improvements in blood sugar control.

The purpose of this study is to determine if tirzepatide is more effective than placebo in improving ovarian function in women with PCOS who have overweight or obesity. Tirzepatide is a medication that helps regulate blood sugar and can promote weight loss. The study will focus specifically on whether the medication can help normalize menstrual cycles in women with PCOS.

Participants will receive either tirzepatide or placebo through self-injection for 72 weeks (approximately 1.5 years). Throughout the study, researchers will track menstrual cycles, measure hormone levels in the blood, monitor changes in body weight and composition, and assess various health indicators related to metabolism and quality of life. Participants will need to avoid hormonal contraceptives during the study period and use alternative barrier methods for contraception.

Participants in the study will receive either dapiglutide or a placebo through injections. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This helps ensure that the results are unbiased. The study will monitor changes in body weight as the primary measure of effectiveness, with additional observations on other health markers such as gut permeability and inflammation levels.

The trial aims to provide valuable insights into the potential of dapiglutide as a treatment for obesity, helping to determine its effectiveness and safety. The study is expected to run for a period of time, during which participants will be closely monitored to assess the impact of the treatment on their weight and overall health.

The main purpose of the study is to observe any changes in MMC activity after administering liraglutide compared to a placebo. Additionally, the study will look at differences in the release of gastrointestinal hormones, hunger sensations, and food intake between those receiving liraglutide and those receiving a placebo. The study will also measure changes in blood glucose levels. Participants will be involved in the study for a period of up to five days, during which they will receive the treatment through subcutaneous injection, meaning the injection is given under the skin.

This trial is particularly relevant for understanding how liraglutide might influence factors related to obesity, even though the participants themselves are healthy volunteers. The study aims to provide insights into how this medication could potentially be used to manage or treat conditions related to weight and appetite control. The trial is expected to conclude by the end of 2025.